Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria candidate AK006 following disappointing Phase I trial results. Also, Merck & Co ...

Sage Therapeutics, Inc. NASDAQ: SAGE) is officially exploring "strategic alternatives" to make shareholders happy. The process includes anything from a possible business combination to a full-on ...

28 January 2025 The headline payment percentage for newer medicines under the Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) has been set at 22.9% for 2025, raising concerns from the ...

Allakos has announced a 75% workforce reduction and the discontinuation of its chronic spontaneous urticaria (CSU) AK006 development programme following underwhelming Phase I results. This ...

SAN CARLOS, Calif. - Allakos Inc . (NASDAQ:ALLK), a clinical-stage biotechnology company with a market capitalization of $108 million, announced today that it will halt the development of its drug ...

Allakos shares collapsed on Monday after the clinical-stage biotechnology company threw in the towel on its AK006 product candidate and said it would slash its workforce by 75%. Shares of Allakos ...